Minireviews
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Urol. Mar 24, 2014; 3(1): 20-30
Published online Mar 24, 2014. doi: 10.5410/wjcu.v3.i1.20
Role of β-microseminoprotein from prostate cancer initiation to recurrence: A mini-review
Nishi Karunasinghe, Karen Bishop, Pamela Murray, Yuanye Xu, Megan Goudie, Lance Ng, Shuotun Zhu, Dug Yeo Han, Lynnette R Ferguson, Jonathan Masters, Benji Benjamin, Michael Holmes
Nishi Karunasinghe, Karen Bishop, Pamela Murray, Shuotun Zhu, Lynnette R Ferguson, Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand
Yuanye Xu, Lance Ng, Dug Yeo Han, Lynnette R Ferguson, Discipline of Nutrition, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand
Megan Goudie, Jonathan Masters, Urology Department, Auckland Hospital, Auckland 1142, New Zealand
Benji Benjamin, Radiology Department, Auckland Hospital, Auckland 1142, New Zealand
Michael Holmes, Urology Department, Waikato Hospital, Hamilton 3204, New Zealand
Author contributions: Karunasinghe N, Bishop K, Ferguson LR and Masters J designed the research onto urinary and serum MSMB assays and urinary PCA3 assays; Goudie M, Ng L, Zhu S, Benjamin B and Holmes M supported with patient recruitment and sample collection; Karunasinghe N, Murray P and Ng L carried out urinary RNA extraction and gene expression assays; Bishop K and Xu Y carried out measurement of MSMB levels; Han DY statistical support; Karunasinghe N wrote the review; Bishop K proof read the manuscript
Correspondence to: Nishi Karunasinghe, PhD, Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand. n.karunasinghe@auckland.ac.nz
Telephone: +64-9-9234609 Fax: +64-9-3737502
Received: November 7, 2013
Revised: January 28, 2014
Accepted: February 16, 2014
Published online: March 24, 2014
Core Tip

Core tip: Potential exists to use the ratio of MSMB full-length and short splice variants as a predictor of prostate cancer recurrence particularly after radiation therapy or surgical procedure or both. Control of the level of full-length splice variant in proportion to the short isoform could also carry a therapeutic use in controlling biochemical recurrence of the disease.